The changing epidemiology of fungal infections: Are the lipid-based forms of amphotericin B an advance?

European Journal of Haematology, Supplement

Volumn 56, Issue 57, 1996, Pages 12-17

  Herbrecht, R ^a,b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

aspergillosis; candidiasis; invasive fungal infections; lipid based amphotericin B

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; LIPID;

ASPERGILLOSIS; CANCER; CANDIDA; CONFERENCE PAPER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MYCOSIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; INCIDENCE; REVIEW;

AMPHOTERICIN B; HUMANS; INCIDENCE; LIPIDS; MYCOSES;

EID: 0029716561     PISSN: 09024506     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. BECK-SAGUÉ CM, JARVIS WR AND THE NATIONAL NOSOCOMIAL INFECTIONS SURVEILLANCE SYSTEM. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993: 167: 1247-1251.
2. GROLL A, SHAH PM, MENTZEL C, SCHNEIDER M. Changing pattern of invasive mycosis at autopsy. Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994: 106 (abst J109).
3. PFALLER MA. Epidemiology and control of fungal infections. Clin Infect Dis 1994: 19 (suppl 1): S8-S13.
4. WEY SB, MORI M, PFALLER MA, WOOLSON RF, WENZEL RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988: 148: 2642-2645.
5. BODEY G, BUELTMANN B, DUGUID W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992: 1: 99-109.
6. BLERIOT JP. Candidoses invasives graves. Importance du phénomène et tableaux cliniques. Réan Soins Intens Méd Urg 1990: 6: 597-609.
7. RANGEL-FRAUSTO MS, MARTIN MA, SAIMAN L, BLUMBERG H, PATERSON JE, PFALLER MA, WENZEL RP AND THE NEMIS STUDY GROUP. High prevalence of Candida spp. on hands of health care workers in surgical and neonatal intensive care units: a multicenter study. Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994: 105 (abstr J106).
8. MAKSYMIUK AW, THONGPRASERT S, HOPFER R, LUNA M, FAINSTEIN V, BODEY GP. Systemic candidiasis in cancer patients. Am J Med 1984: 77 (suppl 4D): 20-27.
9. KOMSHIAN SV, UWAYDAH AK, SOBEL JD, CRANE LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989: 11: 379-485.
10. WINGARD JR, MERZ WG, RINALDI MG, JOHNSON TR, KARP JE, SARAL R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991: 325: 1274-1277.
11. DENNING DW. Can we prevent azole resistance in fungi? Lancet 1995: 346: 454-455.
12. DUBOIS D, VAN BURIK J-A, DAVIS C, LEISENRING W, BOWDEN RA. Emergence of non-Candida albicans fungemia in bone marrow transplant patients receiving fluconazole. Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994: 9 (abstr J6).
13. WEY SB, MORI M, PFALLER MA, WOOLSON RF, WENZEL RP. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989: 149: 2349-2353.
14. KARABINIS A, HILL C, LECLERCQ B, TANCREDE C, BAUME D, ANDREMONT A. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988: 26: 429-432.
15. REX JH, BENNETT JE, SUGAR AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994: 331: 1325-1330.
16. DENNING DW, LEE JY, HOSTETLER JS, et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994: 97: 135-144.
17. DENNING DW, STEVENS DA. Antifungal and surgical treatment of invasive aspergillosis. Review of 2121 published cases. Rev Infect Dis 1990: 12: 1147-1201.
18. RINGDEN O, MEUNIER F, TOLLEMAR J, et al. Efficacy of amphotericin B encapsulated in liposomes (Ambisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991: 28 (suppl B): 73-82.
19. CHOPRA R, BLAIR S, STRANG J, CERVI P, PATTERSON KG, GOLDSTONE AH. Liposomal amphotericin B (Ambisome) in the treatment of fungal infection in neutropenic patients. J Antimicrob Chemother 1991: 28 (suppl B): 93-104.
20. OPPENHEIM BA, HERBRECHT R, KUSNE S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995: 21: 1145-1153.
21. WALSH TJ, HIEMENZ JW, SEIBEL N, ANAISSIE EJ. Amphotericin B Lipid Complex in the treatment of 228 cases of invasive mycosis. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 1994: 247 (abstr M69).
22. LISTER J. Amphotericin B Lipid Complex in the management of serious systemic mycoses in patients intolerant to amphotericin B therapy. Blood 1994: 84 (suppl 1): 306a (abstr 1209).
23. Data on file. The Liposome Company, 1993.
24. HERBRECHT R, KOENIG H, WALLER J, LIU KL, GUÉHO E. Trichosporon infections: clinical manifestations and treatment. J Mycol Med 1993: 3: 129-136.